Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Diabetes|May 18, 2026
Growth Differentiation Factor-15 in Diabetic Kidney and Cardiovascular Disease: Pathogenic Driver or Protective ModulatorAmani Slika, Maya Noureddine, Dalal Jomaa, et al.
ACS Chemical Biology|June 2, 2025
Novel Lipophagy Inducers as Potential Therapeutics for Lipid Metabolism DisordersRachel Njeim, Bassel Awada, Haley Donow, et al.
Pharmaceutics|March 29, 2023
SGLT2 Inhibitor-Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling MechanismBatoul Dia, Sahar Alkhansa, Rachel Njeim, et al.
Journal of Advanced Research|February 1, 2023
Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney diseasePamela Houeiss, Rachel Njeim, Hani Tamim, et al.
American Journal of Physiology. Renal Physiology|July 4, 2024
Oxysterol-binding protein-like 7 deficiency leads to ER stress-mediated apoptosis in podocytes and proteinuriaJoanne Duara, Maria Torres, Margaret Gurumani, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Modulation of the APOM/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux MechanismsMatthew Tolerico, Arianna Insenga, Judith Molina, et al.
Diabetes|January 20, 2023
VEGF-A: A Novel Mechanistic Link Between CYP2C-Derived EETs and Nox4 in Diabetic Kidney DiseaseRachel Njeim, Kawthar Braych, Hilda E Ghadieh, et al.
International Journal of Molecular Sciences|December 17, 2024
Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome PodocytesJin-Ju Kim, Eun-Jeong Yang, Judith Molina David, et al.
Diabetes|March 11, 2026
Mesenchymal Stem Cell and Secretome Treatments Inhibit the mTOR-NOX4 Pathway in Diabetic Kidney DiseaseRachel Njeim, Sahar Alkhansa, Sarah Almoussawi, et al.
Pharmaceutics|July 27, 2024
Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β InhibitionLayal Abou Assi, Sahar Alkhansa, Rachel Njeim, et al.
Pageof 3